- 全部删除
您的购物车当前为空
KYN-101 是一种具有口服活性和选择性的芳基烃受体(AHR)抑制剂,具有抗癌活性。KYN-101 降低 CYP1A1 mRNA 表达,可用于研究乳腺癌和急性髓系白血病。


为众多的药物研发团队赋能,
让新药发现更简单!
KYN-101 是一种具有口服活性和选择性的芳基烃受体(AHR)抑制剂,具有抗癌活性。KYN-101 降低 CYP1A1 mRNA 表达,可用于研究乳腺癌和急性髓系白血病。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 677 | In stock | |
| 5 mg | ¥ 1,490 | In stock | |
| 10 mg | ¥ 2,320 | In stock | |
| 25 mg | ¥ 4,290 | In stock | |
| 1 mL x 10 mM (in DMSO) | ¥ 1,260 | In stock |
KYN-101 相关产品
| 产品描述 | KYN-101 is an orally active and selective aryl hydrocarbon receptor (AHR) inhibitor with anticancer activity. KYN-101 decreases CYP1A1 mRNA expression and can be used in the study of breast cancer and acute myeloid leukemia. KYN-101 is an orally active and selective aryl hydrocarbon receptor (AHR) inhibitor with anticancer activity. |
| 体内活性 | KYN-101(10 mg/kg;每天一次,持续 12 天;口服给药)处理 6-8 周龄的 C57BL/6 J小鼠(B16IDO 肿瘤荷载小鼠)能够显著减少肿瘤生长。此外,KYN-101与抗 PD-1 抗体联合使用能够进一步延缓肿瘤生长并延长 CT26 模型中小鼠的生存期[1]。 |
| 别名 | KYN101, KYN 101 |
| 分子量 | 386.43 |
| 分子式 | C22H19FN6 |
| CAS No. | 2247950-73-6 |
| Smiles | FC1=CN=CC(=C1)C2=NC3=C(C=NN3C(=C2)NCCC4=CNC=5C=CC=CC54)C |
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| 溶解度信息 | DMSO: 80 mg/mL (207.03 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
评论内容